Drug General Information (ID: DDIFG5D0RA)
Drug Name			Alemtuzumab		Drug Info		Belantamab mafodotin		Drug Info
Drug Type		Monoclonal antibody				Monoclonal antibody
Therapeutic Class		Antineoplastics				Antineoplastics

Mechanism of Alemtuzumab-Belantamab mafodotin Interaction (Severity Level: Moderate)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Alemtuzumab				Belantamab mafodotin
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Alemtuzumab and Belantamab mafodotin

Recommended Action
Management		Caution is advised if alemtuzumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. The manufacturer recommends that single doses of alemtuzumab not exceed 30 mg and cumulative weekly doses not exceed 90 mg, since higher dosages are associated with an increased incidence of pancytopenia. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.

References
1	Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.